# Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

> **NCT07220252** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **TG Therapeutics, Inc.** · enrollment: 240 (estimated)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Ublituximab
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Fingolimod

## Key facts

- **NCT ID:** NCT07220252
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2030-01-01
- **Final completion:** 2033-06-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07220252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07220252, "Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT07220252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*